Olaf Merkel

Summary

Affiliation: Paracelsus Private Medical University
Country: Austria

Publications

  1. ncbi Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia
    O Merkel
    Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology of the Paracelsus Medical University Hospital, Salzburg, Austria
    Leukemia 26:2508-16. 2012
  2. ncbi Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, Third Medical Department, Paracelsus Medical University Salzburg, Mullner Hauptstrasse 48, 5020 Salzburg, Austria
    Mol Cancer Ther 10:1127-36. 2011
  3. ncbi Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University Salzburg, Salzburg, Austria
    J Mol Med (Berl) 86:541-52. 2008
  4. ncbi Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, Third Medical Department With Hematology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
    Proc Natl Acad Sci U S A 107:16228-33. 2010
  5. ncbi Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology of the Paracelsus Medical University Salzburg, Salzburg, Austria
    Cell Cycle 9:2764-8. 2010
  6. ncbi microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia
    Daniela Asslaber
    Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University Salzburg, Salzburg, Austria
    Blood 115:4191-7. 2010
  7. ncbi Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation
    Johannes A Mayr
    Department of Pediatrics, Paracelsus Private Medical University, Salzburg, Austria
    Am J Hum Genet 80:478-84. 2007
  8. ncbi Novel treatment avenues for peripheral T-cell lymphomas
    Georg Hopfinger
    3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology of the Paracelsus Private Medical University, Laboratory for Immunological and Molecular Cancer Research, Mullner Hauptstrasse 48, 5020 Salzburg, Austria
    Expert Opin Drug Discov 7:1149-63. 2012
  9. ncbi Presence and potential signaling function of N-acylethanolamines and their phospholipid precursors in the yeast Saccharomyces cerevisiae
    Olaf Merkel
    Institute for Molecular Biosciences, University of Graz, A 8010 Graz, Austria
    Biochim Biophys Acta 1734:215-9. 2005
  10. ncbi Regulation of activity in vitro and in vivo of three phospholipases B from Saccharomyces cerevisiae
    Olaf Merkel
    , , Petersgasse 12, 8010 Graz, Austria
    Biochem J 387:489-96. 2005

Collaborators

Detail Information

Publications11

  1. ncbi Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia
    O Merkel
    Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology of the Paracelsus Medical University Hospital, Salzburg, Austria
    Leukemia 26:2508-16. 2012
    ..Tumor load reduction was coupled to BCL2 downregulation. Our results identify the clinically approved compound actinomycin D as a potentially valuable treatment option for CLL high-risk patients...
  2. ncbi Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, Third Medical Department, Paracelsus Medical University Salzburg, Mullner Hauptstrasse 48, 5020 Salzburg, Austria
    Mol Cancer Ther 10:1127-36. 2011
    ..Also, CD30 antibodies that have been tested in ALCL for quite a while will probably find a place in forthcoming treatment strategies...
  3. ncbi Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University Salzburg, Salzburg, Austria
    J Mol Med (Berl) 86:541-52. 2008
    ..The high activity of As2O3 in B-CLL cells from high-risk patients makes it a promising drug for high-risk and/or fludarabine-refractory B-CLL patients...
  4. ncbi Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, Third Medical Department With Hematology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
    Proc Natl Acad Sci U S A 107:16228-33. 2010
    ..In addition to future therapeutical and diagnostic applications, it will be of interest to study the physiological implications and prognostic value of the identified miRNA profiles...
  5. ncbi Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia
    Olaf Merkel
    Laboratory for Immunological and Molecular Cancer Research, IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology of the Paracelsus Medical University Salzburg, Salzburg, Austria
    Cell Cycle 9:2764-8. 2010
    ..Here, we present data showing that knockdown of p53 in HCT-116 cells severely reduces miR-34a induced apoptosis. In conclusion, miR-34a is proposed as a marker for the activity of the p53 pathway in CLL...
  6. ncbi microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia
    Daniela Asslaber
    Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University Salzburg, Salzburg, Austria
    Blood 115:4191-7. 2010
    ..Further, overexpression of miR-34a in primary B-CLL cells induced apoptosis. These findings suggest miR-34a as a possible therapeutic avenue and a sensitive indicator of the activity of the p53 axis in B-CLL...
  7. ncbi Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation
    Johannes A Mayr
    Department of Pediatrics, Paracelsus Private Medical University, Salzburg, Austria
    Am J Hum Genet 80:478-84. 2007
    ..The enzyme defect was confirmed by complementation analysis in yeast. This is the first report of patients with mitochondrial phosphate-carrier deficiency...
  8. ncbi Novel treatment avenues for peripheral T-cell lymphomas
    Georg Hopfinger
    3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology of the Paracelsus Private Medical University, Laboratory for Immunological and Molecular Cancer Research, Mullner Hauptstrasse 48, 5020 Salzburg, Austria
    Expert Opin Drug Discov 7:1149-63. 2012
    ..This refinement will allow treatments to be prepared according to the need of the individual patient...
  9. ncbi Presence and potential signaling function of N-acylethanolamines and their phospholipid precursors in the yeast Saccharomyces cerevisiae
    Olaf Merkel
    Institute for Molecular Biosciences, University of Graz, A 8010 Graz, Austria
    Biochim Biophys Acta 1734:215-9. 2005
    ....
  10. ncbi Regulation of activity in vitro and in vivo of three phospholipases B from Saccharomyces cerevisiae
    Olaf Merkel
    , , Petersgasse 12, 8010 Graz, Austria
    Biochem J 387:489-96. 2005
    ..Deletion mutants defective in the PLB1 gene are significantly more resistant to SDS than are wild-type cells...
  11. ncbi Structure and function of the BAH-containing domain of Orc1p in epigenetic silencing
    Zhiguo Zhang
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
    EMBO J 21:4600-11. 2002
    ..These data are consistent with the view that the Orc1p-Sir1p interaction at the E silencers ensures stable inheritance of pre-established Sir2p, Sir3p and Sir4p complexes at the silent mating type loci...